. . "Mazindol"@en . . . "Although the mechanism of action of the sympathomimetics in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Unlike other sympathomimetic appetite suppressants such as phentermine, mazindol is thought to inhibit the reuptake of norepinephrine rather than to cause its release."@en . . . . . . "Symptoms of a mazindol overdose include restlessness, tremor, rapid breathing, confusion, hallucinations, panic, aggressiveness, nausea, vomiting, diarrhea, an irregular heartbeat, and seizures."@en . "22232-71-9"@en . . . . "Mazindol is a tricyclic anorexigenic agent unrelated to and less toxic than amphetamine, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter. Mazindol is only approved in the United States for the treatment of Duchenne muscular dystrophy, and is not marketed or available in the United States for use in the treatment of obesity."@en . . . . . . . "10-13 hours"@en . "Mazindol"@en . "Used in short-term (a few weeks) treatment of exogenous obesity in conjunction with a regimen of weight reduction based on caloric restriction, exercise, and behavior modification in patients with a body mass index of 30 kg of body weight per height in meters squared (kg/m²) or in patients with a body mass index of 27 kg/m² in the presence of risk factors such as hypertension, diabetes, or hyperlipidemia."@en . . . . . . "Mazindolum"@en . . . . . . "If product causes GI problems, it can be taken during meals."@en . . "approved"@en . . "U.S. Patents 3,597,445 and 3,763,178."@en . "Humans and other mammals"@en . " "@en . . . . . . "May be taken without regard to meals, but preferably 1 hour before a meal."@en . . "Sanorex"@en . . . . . . "Mazindolo"@en . . .